Plus Therapeutics Names Eric Daniels as CDO to Advance REYOBIQ and CNS Pipeline
Plus Therapeutics named Eric J. Daniels, M.D., MBA, as Chief Development Officer effective April 20, 2026. Daniels’s two decades of clinical, regulatory and operational experience is expected to accelerate advancement of REYOBIQ™ and the broader CNS-focused radiotherapeutic pipeline.
1. Appointment Details
Plus Therapeutics appointed Eric J. Daniels, M.D., MBA, as Chief Development Officer effective April 20, 2026, to oversee clinical development and regulatory strategy across its precision diagnostics and radiotherapeutics portfolio.
2. Professional Background
Daniels brings over 20 years of biotech leadership experience, having led development portfolios at Kiora Pharmaceuticals and co-founded Bayon Therapeutics, with prior executive roles at OccuRx and strategic contributions at Cytori Therapeutics.
3. Strategic Impact
His expertise in clinical, preclinical and CMC activities is expected to accelerate advancement of REYOBIQ™ trials and enhance execution of the company’s CNS oncology pipeline, bolstering strategic and operational capabilities.